Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30874634 | 0.85 | TAAR1 (0.51) | SMN1; SMN2KDM4ERIPK1LMNAMAPK1 | |
| SCHEMBL661699 | 0.85 | TAAR1 (0.51) | SMN1; SMN2KDM4ERIPK1LMNAMAPK1 | |
| SCHEMBL2972991 | 0.84 | MEP1B (0.48) | SMN1; SMN2KDM4ELMNAALDH1A1CYP4F2 | |
| SCHEMBL16112668 | 0.84 | P2RX7 (0.45) | SMN1; SMN2KDM4ERIPK1LMNAMAPK1 | |
| SCHEMBL16396591 | 0.84 | ANO1 (0.47) | SMN1; SMN2KDM4ELMNAMAPK1ALDH1A1 | |
| SCHEMBL6445445 | 0.84 | RIPK1 (0.42) | RIPK1CES2CES1CYP4F2CYP4A11 | |
| Hydrochloric Acid SCHEMBL27592315 | 0.84 | TAAR1 (0.50) | SMN1; SMN2KDM4ERIPK1LMNAMAPK1 | |
| SCHEMBL5009319 | 0.83 | NLRP3 (0.50) | SMN1; SMN2KDM4ERIPK1ALDH1A1CYP4F2 | |
| SCHEMBL31284578 | 0.83 | KDM4E (0.43) | SMN1; SMN2KDM4ELMNAMAPK1ALDH1A1 | |
| SCHEMBL18261999 | 0.83 | KDM4E (0.43) | SMN1; SMN2KDM4ELMNAALDH1A1CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163039-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2025-05-22 | — | — | US | disclosed |
| EP-4252755-B1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LTD (GB) | 2025-05-14 | — | — | EP | disclosed |
| US-20250084075-A1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LIMITED (GB) | 2025-03-13 | — | — | US | disclosed |
| EP-4452964-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2024-10-30 | — | — | EP | disclosed |
| US-12098148-B2 | Therapeutic compounds | C4X DISCOVERY LIMITED (GB) | 2024-09-24 | — | — | US | disclosed |
| CN-118339153-A | Heteroaromatic compounds for the treatment of cancer | 勃林格殷格翰国际有限公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-4252755-A2 | THERAPEUTIC COMPOUNDS | C4x Discovery Limited (GB) | 2023-10-04 | — | — | EP | disclosed |
| EP-4252755-A2 | THERAPEUTIC COMPOUNDS | C4x Discovery Limited (GB) | 2023-10-04 | — | — | EP | disclosed |
| EP-3870578-B1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LTD (GB) | 2023-08-16 | — | — | EP | disclosed |
| EP-3870578-B1 | THERAPEUTIC COMPOUNDS | C4X DISCOVERY LTD (GB) | 2023-08-16 | — | — | EP | disclosed |
| US-20110065696-A1 | IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF | KIMURA TEIJI | 2011-03-17 | — | — | US | disclosed |
| US-20110009619-A1 | POLYCYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2181992-A1 | POLYCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2010-05-05 | — | — | EP | disclosed |
| EP-1411046-B1 | QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF-PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN PHARMA KK (JP) | 2009-09-16 | — | — | EP | disclosed |
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ARRAY BIOPHARMA, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2009-03-05 | — | — | US | disclosed |
| WO-2008078350-A2 | PROCESS FOR THE PREPARATION OF FLUOROPHENYLACETIC ACIDS AND DERIVATIVES THEREOF | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2008-07-03 | — | — | WO | disclosed |
| CN-1934088-A | As 5-HT2c6-substituted 2,3,4, 5-tetrahydro-1H-benzo [ d ] receptor agonists]Aza * | LILLY CO ELI (US) | 2007-03-21 | — | — | CN | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | HTR2C, HTR5A, HTR4 | SMN1; SMN2 1853/4885KDM4E 1208/4885RIPK1 3054/4885 |
| US-20110009619-A1 | POLYCYCLIC COMPOUND | APP, BACE1, PSEN1 | SMN1; SMN2 1063/4885KDM4E 4536/4885RIPK1 2278/4885 |
| US-20250163039-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | NRAS, KRAS, RB1 | SMN1; SMN2 4332/4885KDM4E 2708/4885RIPK1 3228/4885 |
| US-12098148-B2 | Therapeutic compounds | NFE2L2, KEAP1, NQO1 | SMN1; SMN2 774/4885KDM4E 3963/4885RIPK1 4337/4885 |
| US-20110065696-A1 | IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF | APP, PSEN1, BACE1 | SMN1; SMN2 288/4885KDM4E 3909/4885RIPK1 2091/4885 |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | APP, BACE1, PSEN1 | SMN1; SMN2 420/4885KDM4E 4155/4885RIPK1 3256/4885 |
| US-20250084075-A1 | THERAPEUTIC COMPOUNDS | NFE2L2, KEAP1, NQO1 | SMN1; SMN2 774/4885KDM4E 3963/4885RIPK1 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.